AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
TPD
Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...
HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica,...
Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial...
Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...
Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
Shanghai Leadingtac Pharmaceutical Co., Ltd., a China-based small molecule drug developer, has announced the successful...
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...
Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders
US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical...
Huadong Medicine Gets Green Light for HPK1 PROTAC Drug HDM2006 in Advanced Solid Tumors
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases
Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and...
Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it...
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...
BeiGene Advances R/R CLL/SLL Treatment with FDA Fast-Tracked BGB-16673 in Phase I/II Clinical Trial
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has been granted Fast...
Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S....
Degen Biopharmaceutical’s DG01 PROTAC Drug Receives NMPA Clearance for Solid Tumor Studies
Suzhou Degen Biopharmaceutical Co., Ltd, a leading specialist in PROteolysis TArgeting Chimeras (PROTAC) technology in...
Hengrui Pharmaceuticals Advances in Breast Cancer Treatment with NMPA Clinical Trial Greenlight
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a pharmaceutical heavyweight based in China, has received...
Jiangsu Hengrui Receives NMPA Approval to Study CDK 4/6 Inhibitor Dalpiciclib in Combination with HRS-1358 for Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has received...
Kymera Therapeutics’ Stock Soars on Sanofi’s Plans to Expand KT-474 Clinical Trials
Kymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical company based in the U.S., has announced that...